Hansa Biopharma — Oktober 2023
-
At the intersection of patient-centered care and disruptive science
At the intersection of patient-centered care | Hansa Biopharma and disruptive science
How Eurotransplant is advancing kidney transplantation for highly sensitized patients with imlifidase.
(www.hansabiopharma.com)
(24/10 - Hansa Biopharma - News and insights)
How Eurotransplant is advancing kidney transplantation for highly sensitized patients with imlifidase ....
-
"To date, the Desensitization Program has identified 173 highly sensitized patients that have been on the wait list for more than 5 years. Centers in the Eurotransplant network are now able to offer these patients a transplant once a suitable organ is allocated."
-
Hansa Biopharma Interim Report January-September 2023
Total Q3 revenue of SEK 22.8m including SEK 16.5m in product sales and SEK 5.7m under our agreement with Sarepta
-
TOCKHOLM (Nyhetsbyrån Direkt) Bioteknikbolaget Hansa Biopharma redovisar ett rörelseresultat för det tredje kvartalet 2023 på -202 miljoner kronor (-140).
Nettoomsättningen sjönk till 22,8 miljoner kronor (67,1).Nettoresultatet sjönk till -251 miljoner kronor (-154).
-
-
CC (26 October 2023 14:00 CEST): https://hansabiopharma.eventcdn.net/events/q3-2023-conference-call
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind